Phio Pharmaceuticals Corp. (NasdaqCM: PHIO)
Health Care · Biotechnology · US
$1.14
-3.39% today · -40.7% 1Y
Phio Pharmaceuticals Corp. (NasdaqCM: PHIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $13.71M and employs 6 people.
Over the last twelve months the share price has lost 40.7%, trading between 0.81 and 4.19.
Tweenvest scores Phio Pharmaceuticals Corp. across four factors: quality 26/100. Its strongest factor is quality.
PHIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.71M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.36
- Dividend yield
- —
- Beta (5Y)
- 0.79
- 52-week high
- $4.19
- 52-week low
- $0.81
- Avg volume (3M)
- —
- Shares outstanding
- 11.62M
- Employees
- 6
- Next earnings
- —
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
- ISIN
- US71880W5013
- Founded
- 2003
- Listed since
- May 10, 2012
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.83 | +2.12% |
Figures last refreshed Aug 18, 2026.